Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study
Open Access
- 12 February 2021
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 27 (3), 398-407
- https://doi.org/10.1111/hae.14270
Abstract
Introduction Real‐world data on health‐related outcomes in persons with haemophilia A (PwHA) can provide useful information for improving patient care. The global, non‐interventional study (NIS; NCT02476942) prospectively collected high‐quality data in PwHA, including those without factor VIII (FVIII) inhibitors treated according to local routine clinical practice. Aim To report health‐related quality of life (HRQoL) and health status of adult/adolescent PwHA without FVIII inhibitors. Methods Participants were PwHA without FVIII inhibitors age ≥12 years; they remained on existing episodic treatment or prophylaxis. HRQoL was assessed by Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL) or Haemophilia‐Specific Quality of Life Assessment for Children and Adolescents Short Form (Haemo‐QoL‐SF II). Health status was assessed through EuroQol 5‐Dimensions 5‐Levels (EQ‐5D‐5L) index utility score and visual analogue scale (EQ‐VAS). Results Ninety‐four participants enrolled; median age was 34.0 years (range 12–76). Forty‐five received episodic treatment and 49 received prophylaxis for a median time of 27.7 weeks and 30.4 weeks, respectively. Mean (standard deviation) baseline Haem‐A‐QoL total scores were 40.1 (17.0) for the episodic group and 26.6 (14.6) for the prophylaxis group, indicating impairments in HRQoL, which remained consistent over time. Mean EQ‐5D‐5L IUS scores were similar between treatment regimens (0.8 episodic; 0.9 prophylaxis) and consistent over time. The mean EQ‐VAS scores were similar between treatment regimens, and lower on days when bleeding occurred (79.0 vs 85.0 for episodic treatment; 77.0 vs 82.0 for prophylaxis, respectively). Conclusions Adult and adolescent PwHA without FVIII inhibitors had HRQoL impairments regardless of whether they were treated with episodic or prophylactic standard care with FVIII.Keywords
This publication has 29 references indexed in Scilit:
- Benefits and limitations of extended plasma half-life factor VIII products in hemophilia AExpert Opinion on Investigational Drugs, 2020
- Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS)Haemophilia, 2019
- Practical aspects of extended half-life products for the treatment of haemophiliaTherapeutic Advances in Hematology, 2018
- Monitoring joint health in haemophilia: Factors associated with deteriorationHaemophilia, 2017
- Social/economic costs and quality of life in patients with haemophilia in EuropeThe European Journal of Health Economics, 2016
- Haemophilia in a real‐world setting: the value of clinical experience in data collectionEuropean Journal of Haematology, 2016
- The current status of prophylactic replacement therapy in children and adults with haemophiliaBritish Journal of Haematology, 2015
- Burden of Disease Resulting from Hemophilia in the U.S.American Journal of Preventive Medicine, 2010
- Recombinant factor VIII in the management of hemophilia A: current use and future promiseTherapeutics and Clinical Risk Management, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007